

Updates of the NCCN guidelines for non-small cell lung cancer

Liu Huang (✉)

Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

Updates in version 4.2018 of the NCCN guidelines for non-small cell lung cancer from version 3.2018

NSCL-J 2 of 4

Adenocarcinoma, Large Cell, NSCLC NOS (PS 0–1)
Pembrolizumab/cisplatin/pemetrexed added as a first-line therapy option.

NSCL-J 4 of 4

Reference added: Gandhi L, Rodriguez-Abreu D, Gadgeel S, *et al.* Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. *N Engl J Med* 2018 [published online April 16, 2018].

Updates in version 3.2018 of the NCCN guidelines for non-small cell lung cancer from version 2.2018

DIAG-3

Solitary part-solid nodule(s); sub-categories modified: Persistent and < 6 mm, delete “solid component”;

Persistent and ≥ 6 mm, delete “solid component”.

Sub-bullets added: If unchanged and solid component remains < 6 mm, annual CT for 5 y; If solid component ≥ 6 mm, consider PET/CT or biopsy.

Updates in Version 2.2018 of the NCCN Guidelines for Non-Small Cell Lung Cancer from Version 1.2018 include:

NSCL-4 and NSCL-6

Added Stage IIIA (T4, N0-1)

NSCL-17

Testing results clarification added: EGFR, ALK, ROS1, BRAF negative or unknown, PD-L1 < 50% or unknown

NSCL-J 2 of 4 and 3 of 4

Footnote ** added: Carboplatin-based regimens are often used for patients with comorbidities or those who cannot tolerate cisplatin.

MS-1

The Discussion section has been updated to reflect the changes in the algorithm.